Ignite Creation Date:
2024-05-06 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 12:50 PM
Study NCT ID:
NCT03600909
Status:
TERMINATED
Last Update Posted:
2022-04-12
First Post:
2018-07-17
Brief Title:
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan Cyclophosphamide and Fludarabine
Status:
TERMINATED
Status Verified Date:
2021-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Accrual has been slow
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this study is to see if the study therapy can decrease the chemotherapy-related side effects while maximizing the effectiveness of disease control The physicians will also be studying the effect of removing T-cells from the donors stem cells before transplant T-cells are a type of white blood cell that may help cause a serious side effect of transplant called Graft versus Host Disease GVHD The way it removes the T-cells from the donor stem cells is actually by selecting only the stem cells called CD34 cells by using a device called CliniMACS This process is called CD34 selection The CliniMACS device is currently under the supervision of the FDA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None